The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKanabo Grp Plc Regulatory News (KNB)

Share Price Information for Kanabo Grp Plc (KNB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.75
Bid: 1.60
Ask: 1.90
Change: 0.00 (0.00%)
Spread: 0.30 (18.75%)
Open: 1.75
High: 1.75
Low: 1.75
Prev. Close: 1.75
KNB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Partnership with BRITISH CANNABISâ„¢

2 Nov 2023 07:00

RNS Number : 1152S
Kanabo Group PLC
02 November 2023
 

 

2 November 2023

 

Kanabo Group Plc

("Kanabo", the "Group" or the "Company")

 

Partnership with BRITISH CANNABIS?

 

Kanabo Group plc (LSE: KNB), the patient-focused provider of digital health services and specialist medicines, including medicinal cannabis, is pleased to announce that it has entered into a partnership with BRITISH CANNABIS? to supply the CBD by BRITISH CANNABIS? range of pharmacy-grade CBD health supplements to patients via a prescription service through the Group's online pain management clinic, Treat It.

 

The partnership will allow doctors to prescribe the CBD by BRITISH CANNABIS? products to patients via the Treat It platform. Focused on secondary care, Treat It enables patients access to healthcare professionals via its secure, digital healthcare platform. These medical professionals deliver a full diagnosis as part of a personalised patient care plan and are able to offer treatments, including the prescription of medicinal cannabis, for individuals seeking relief from chronic pain. By incorporating CBD by BRITISH CANNABIS? products into our offerings, Kanabo continues to increase the accessibility and affordability of high quality, alternative pain management solutions to improve overall patient quality of life.

 

From November, Treat It will also be included in Canndr, an online medicinal cannabis app from BRITISH CANNABIS? which enables patients to select and review quality cannabis medicines on the market, gain consultancy advice and select from a number of suitable prescribing clinics. 

 

Avihu Tamir, Chief Executive Officer of Kanabo, commented:

 

"At Kanabo, we aim to increase medicinal cannabis access for more patients. This partnership allows Treat It doctors to include a wider range of quality CBD supplements in our telemedicine offerings. We're eager to further enhance patient-centric healthcare and treatment options. This partnership is just the beginning, and we hope to announce more expansive collaborations in due course."

 

Steve Batchelor, BRITISH CANNABIS? Marketing Director commented:

 

"We are thrilled to join forces with Treat It to make CBD products from our long-standing pharmacy retail brand accessible to pain patients through prescriptions. This partnership represents a significant step forward in expanding patient choices and empowering doctors to explore naturally-derived supplements, as alternatives to traditional pharmaceutical care paths.

 

"We are also pleased that thousands of long-term CBD customers will have the option to consult with Treat It's network of specialist pain doctors, assessing their own particular needs and determining things like what delivery formats, when and how much CBD they could be taking."

 

Enquiries:

Kanabo Group plc

Avihu Tamir, Chief Executive Officer

Assaf Vardimon, Chief Financial Officer

Ian Mattioli, Non-Executive Chair of the Board

 

via Vigo Consulting

+44 (0)20 7390 0230

Peterhouse Capital Ltd (Financial Adviser)

Eran Zucker / Lucy Williams / Charles Goodfellow

+44 (0)20 7469 0930

Vigo Consulting (Financial Public Relations/Investor Relations)

Jeremy Garcia / Fiona Hetherington / Verity Snow

kanabo@vigoconsulting.com

 +44 (0)20 7390 0230

 

About BRITISH CANNABIS?

 

BRITISH CANNABIS? are pioneers in the UK cannabis industry since 2015, specialising in high-quality CBD products trusted by pharmacists and over 40,000 consumers alike. With over six years of experience and a strong reputation, BRITISH CANNABIS? is dedicated to providing natural wellness solutions and promoting education surrounding CBD.

 

About Kanabo Group plc

 

Kanabo Group plc (LSE:KNB) is a digital health company committed to transforming patient care through its innovative technology platform and specialised treatment offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

 

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. Leveraging its telehealth capabilities, in February 2023, Kanabo launched Treat It - an online clinic focused on chronic pain management providing patients with secondary care.

 

With its two complementary business divisions, Kanabo has established itself as an end-to-end digital health provider, offering telehealth consultations, prescriptions, alongside the delivery of tailored treatments.

 

The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.

 

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

 

Visit www.kanabogroup.com for more information.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABBBMTMTTMTRJ
Date   Source Headline
2nd Dec 20222:59 pmRNSResignation of Auditor
15th Nov 20227:30 amRNSUpdate re: Investment into Hellenic Dynamics
24th Oct 20227:00 amRNSKanabo appointed to BSI Steering Group Committee
30th Sep 20227:01 amRNSInvestor Webinar hosted by Vox Markets
30th Sep 20227:00 amRNSHalf-year Report
30th Aug 20222:37 pmRNSGrant of Options
19th Aug 20225:30 pmRNSAppointment of Auditor
17th Aug 20222:05 pmRNSSecond Price Monitoring Extn
17th Aug 20222:00 pmRNSPrice Monitoring Extension
3rd Aug 20229:05 amRNSSecond Price Monitoring Extn
3rd Aug 20229:00 amRNSPrice Monitoring Extension
30th Jun 20225:02 pmRNSResult of AGM
30th Jun 20223:29 pmRNSAGM Statement
16th Jun 20227:00 amRNSNew Subsidiary
9th Jun 20227:00 amRNSContract Extension
8th Jun 20221:00 pmRNSNotice of AGM
6th Jun 20227:00 amRNSFinal Results
20th May 20227:00 amRNSUpdate on the Acquisition of Materia
3rd May 20227:00 amRNSTotal Voting Rights
19th Apr 20223:00 pmRNSExercise of Options and Total Voting Rights
22nd Mar 20227:00 amRNSBoard Changes
11th Mar 202211:23 amRNSInvestor Updates
9th Mar 20227:00 amRNSMoU with Forbe Ltd
1st Mar 20222:05 pmRNSSecond Price Monitoring Extn
1st Mar 20222:00 pmRNSPrice Monitoring Extension
28th Feb 20222:00 pmRNSTotal Voting Rights
25th Feb 20227:00 amRNSDirector/PDMR Dealing
23rd Feb 20227:00 amRNSBlock listing Interim Review
22nd Feb 20229:05 amRNSSecond Price Monitoring Extn
22nd Feb 20229:00 amRNSPrice Monitoring Extension
22nd Feb 20227:00 amRNSCompany Webinar
21st Feb 20225:30 pmRNSExercise of Put Option
21st Feb 20225:15 pmRNSOversubscribed Placing to Raise £2.25m
21st Feb 20224:54 pmRNSAcquisition of GP Service Ltd
31st Jan 202211:00 amRNSTotal Voting Rights
18th Jan 20227:00 amRNSMateria Announces Trading Update for 4Q22
6th Jan 20224:41 pmRNSSecond Price Monitoring Extn
6th Jan 20224:36 pmRNSPrice Monitoring Extension
31st Dec 202111:41 amRNSTotal Voting Rights
31st Dec 202110:00 amRNSGrant of Options
30th Dec 20211:00 pmRNSAchievement of Milestones
16th Dec 20217:05 amRNSMateria Malta First Sales in Europe
15th Dec 20217:00 amRNSPatent Advancement
7th Dec 20217:00 amRNSSubmission for Bioavailability and Efficacy Trial
6th Dec 20213:45 pmRNSExercise of Options
6th Dec 20217:00 amRNSUK Moves to License e-cigarettes and vaporizers
30th Nov 20214:02 pmRNSTotal Voting Rights
29th Nov 202111:05 amRNSSecond Price Monitoring Extn
29th Nov 202111:00 amRNSPrice Monitoring Extension
26th Nov 202111:57 amRNSKanabo to present at Mello: 29 November 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.